Published in Clin J Am Soc Nephrol on January 07, 2010
Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy | NCT02994303
Fabry disease. Orphanet J Rare Dis (2010) 3.48
Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol (2013) 2.11
Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol (2011) 1.11
Update on role of agalsidase alfa in management of Fabry disease. Drug Des Devel Ther (2011) 1.09
The renal biopsy in the genomic era. Pediatr Nephrol (2012) 0.89
Broad spectrum of Fabry disease manifestation in an extended Spanish family with a new deletion in the GLA gene. Clin Kidney J (2012) 0.83
Clinical practice: proteinuria. Eur J Pediatr (2010) 0.79
Awareness of Fabry disease among rheumatologists--current status and perspectives. Clin Rheumatol (2011) 0.76
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med (2006) 32.81
A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics (1976) 13.83
New equations to estimate GFR in children with CKD. J Am Soc Nephrol (2009) 11.48
The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am (1987) 7.63
Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N Engl J Med (2001) 6.94
Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child (1976) 3.71
Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev (2008) 3.49
A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr (1985) 3.35
Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol (2009) 2.96
Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol (2007) 2.73
Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) (2002) 2.51
Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab (2007) 2.51
Fabry disease in childhood. J Pediatr (2004) 2.20
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant (2009) 2.17
Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int (2002) 2.15
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant (2005) 1.84
Susceptibility of glomerular filtration rate estimations to variations in creatinine methodology: a study in older patients. Ann Clin Biochem (2005) 1.74
The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes (2005) 1.67
Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol (2007) 1.59
Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int (1978) 1.56
Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr (2006) 1.55
Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis (2008) 1.53
Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant (2008) 1.46
Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis (2007) 1.44
Pediatric Fabry disease. Pediatrics (2005) 1.43
Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol (2009) 1.40
Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res (2008) 1.35
The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr (2003) 1.32
The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis (2007) 1.21
Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics (2006) 1.20
Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr (2007) 1.14
Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr (2007) 1.09
Prime time for enzymatic creatinine methods in pediatrics. Clin Chem (2009) 1.08
How to estimate GFR in children. Nephrol Dial Transplant (2008) 1.05
Outcomes of children with proliferative lupus nephritis: the role of protocol renal biopsy. Pediatr Nephrol (2007) 0.95
Early renal failure in Fabry's disease. Am J Kidney Dis (1983) 0.93
Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. Biologics (2008) 0.93
Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice. J Am Soc Nephrol (2007) 0.93
Renal pathological changes in Fabry disease. J Inherit Metab Dis (2001) 0.91
[Fetal pathology in Fabry's disease and mucopolysaccharidosis type I]. Cesk Patol (1998) 0.89
Surveillance renal transplant biopsies and subclinical rejection at three months post-transplant in pediatric recipients. Pediatr Transplant (2007) 0.83
Early prenatal diagnosis of inborn error of metabolism: a case report of a fetus affected with Fabry's disease. Asia Oceania J Obstet Gynaecol (1985) 0.83
Kidney involvement in Anderson-Fabry disease. Contrib Nephrol (1997) 0.81
The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function. Clin Nephrol (2009) 0.81
Childhood thin GBM disease: review of 22 children with family studies and long-term follow-up. Pediatr Nephrol (2005) 0.78
Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis (2010) 3.87
Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol (2010) 3.64
Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med (2002) 3.57
Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med (2006) 3.38
Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis (2004) 2.43
Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes (2003) 2.16
Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol (2005) 2.14
Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes (2007) 2.08
Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab (2004) 1.96
Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney Int (2012) 1.81
An increase in the cell component of the cortical interstitium antedates interstitial fibrosis in type 1 diabetic patients. Kidney Int (2002) 1.80
The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes (2002) 1.79
Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney Int (2012) 1.77
Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol (2013) 1.77
Compassionate use of interventions: results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countries. Trials (2010) 1.77
Ethnic differences in renal responses to furosemide. Hypertension (2008) 1.74
Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. Diabetes (2002) 1.70
The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes (2005) 1.67
Histopathology of diabetic nephropathy. Semin Nephrol (2007) 1.60
Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol (2005) 1.57
Pharmacological chaperone action on G-protein-coupled receptors. Curr Opin Pharmacol (2004) 1.45
Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. Nephrol Dial Transplant (2003) 1.43
The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: the Renin-Angiotensin System Study. Diabetes (2005) 1.40
Podocyte structural parameters do not predict progression to diabetic nephropathy in normoalbuminuric type 1 diabetic patients. Am J Nephrol (2015) 1.39
Nephrogenic diabetes insipidus. Ann Intern Med (2006) 1.38
Low mortality and key aspects of delivery of care for end-stage renal disease in Italy. ScientificWorldJournal (2009) 1.37
Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes (2005) 1.34
Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int (2010) 1.25
Elaboration of a novel technique for purification of plasma membranes from Xenopus laevis oocytes. Am J Physiol Cell Physiol (2006) 1.24
Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol (2010) 1.24
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant (2011) 1.23
Atubular glomeruli and glomerulotubular junction abnormalities in diabetic nephropathy. J Am Soc Nephrol (2003) 1.21
The role of the GX9GX3G motif in the gating of high voltage-activated Ca2+ channels. J Biol Chem (2006) 1.19
Heteroligomerization of an Aquaporin-2 mutant with wild-type Aquaporin-2 and their misrouting to late endosomes/lysosomes explains dominant nephrogenic diabetes insipidus. Hum Mol Genet (2002) 1.18
Proposed pathogenesis of idiopathic loin pain-hematuria syndrome. Am J Kidney Dis (2006) 1.18
Diabetes and nephropathy. Curr Opin Nephrol Hypertens (2003) 1.16
Prevention of chronic kidney and vascular disease: toward global health equity--the Bellagio 2004 Declaration. Kidney Int Suppl (2005) 1.16
Glomerulotubular junction abnormalities are associated with proteinuria in type 1 diabetes. J Am Soc Nephrol (2006) 1.16
Enhancing the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol (2006) 1.14
Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep (2013) 1.09
Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials. Clin J Am Soc Nephrol (2013) 1.08
Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol (2008) 1.07
How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin Chim Acta (2010) 1.06
Cell-biologic and functional analyses of five new Aquaporin-2 missense mutations that cause recessive nephrogenic diabetes insipidus. J Am Soc Nephrol (2002) 1.06
Reversed polarized delivery of an aquaporin-2 mutant causes dominant nephrogenic diabetes insipidus. J Cell Biol (2003) 1.05
GFR-estimating models in kidney transplant recipients on a steroid-free regimen. Nephrol Dial Transplant (2010) 1.04
Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol Endocrinol (2004) 1.04
Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol (2014) 1.04
Comparison of methods for counting cells in the mouse glomerulus. Nephron Exp Nephrol (2006) 1.03
Effect of Notch activation on the regenerative response to acute renal failure. Am J Physiol Renal Physiol (2009) 1.03
Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension? Am J Physiol Renal Physiol (2010) 1.03
Diabetic nephropathy: diabetic nephropathy-challenges in pathologic classification. Nat Rev Nephrol (2010) 1.01
Renal lesions predict progression of diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol (2013) 1.01
Cellular basis of diabetic nephropathy: II. The transforming growth factor-beta system and diabetic nephropathy lesions in type 1 diabetes. Diabetes (2002) 1.00
Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. J Am Soc Nephrol (2005) 1.00
The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. Am J Physiol Renal Physiol (2014) 1.00
Two novel aquaporin-2 mutations responsible for congenital nephrogenic diabetes insipidus in Chinese families. J Clin Endocrinol Metab (2002) 1.00
Effects of duration and age at onset of type 1 diabetes on preclinical manifestations of nephropathy. Diabetes (2003) 0.99
Strategies for national health care systems in emerging countries: the case of screening and prevention of renal disease progression in Bolivia. Kidney Int Suppl (2005) 0.99
Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab (2007) 0.98
Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study. Health Policy (2012) 0.97
Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients. Pediatr Endocrinol Rev (2008) 0.97
Fabry disease: dose matters. J Am Soc Nephrol (2014) 0.97
The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus: the renin-angiotensin system study. Ophthalmology (2006) 0.96
Albumin excretion rate in normal adolescents: relation to insulin resistance and cardiovascular risk factors and comparisons to type 1 diabetes mellitus patients. Clin J Am Soc Nephrol (2008) 0.96
A validated disease severity scoring system for Fabry disease. Mol Genet Metab (2009) 0.95
Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus. Nephron Physiol (2009) 0.95
Targeted inactivation of EGF receptor inhibits renal collecting duct development and function. J Am Soc Nephrol (2010) 0.94
Podocyte disorders: Core Curriculum 2011. Am J Kidney Dis (2011) 0.94
New autosomal recessive mutations in aquaporin-2 causing nephrogenic diabetes insipidus through deficient targeting display normal expression in Xenopus oocytes. J Physiol (2010) 0.94
Typical investigational medicinal products follow relatively uniform regulations in 10 European Clinical Research Infrastructures Network (ECRIN) countries. Trials (2012) 0.94
Renal complications of Fabry disease in children. Pediatr Nephrol (2012) 0.93
Diabetic nephropathy is associated with gene expression levels of oxidative phosphorylation and related pathways. Diabetes (2006) 0.92
Kidney failure: aims for the next 10 years and barriers to success. Lancet (2013) 0.91
Schimke immuno-osseous dysplasia: a clinicopathological correlation. J Med Genet (2006) 0.91
Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products. Diabetes Care (2013) 0.90
Characterization of D150E and G196D aquaporin-2 mutations responsible for nephrogenic diabetes insipidus: importance of a mild phenotype. Am J Physiol Renal Physiol (2009) 0.89
Progression of diabetic nephropathy in type 1 diabetic patients. Diabetes Res Clin Pract (2008) 0.89
A novel mechanism in recessive nephrogenic diabetes insipidus: wild-type aquaporin-2 rescues the apical membrane expression of intracellularly retained AQP2-P262L. Hum Mol Genet (2004) 0.89
Prevention programmes of progressive renal disease in developing nations. Nephrology (Carlton) (2006) 0.89
Gene expression differences in skin fibroblasts in identical twins discordant for type 1 diabetes. Diabetes (2012) 0.89
Kidney prevention recipes for your office practice. Kidney Int Suppl (2005) 0.88
Protective effects of PPARγ agonist in acute nephrotic syndrome. Nephrol Dial Transplant (2011) 0.88
Expression and functionality of the Na+/myo-inositol cotransporter SMIT2 in rabbit kidney. Biochim Biophys Acta (2007) 0.87
Lithium, cyclic AMP signaling, A-kinase anchoring proteins, and aquaporin-2. J Am Soc Nephrol (2006) 0.87
Pathophysiology of disease progression in proteinuric nephropathies. Kidney Int Suppl (2005) 0.86
Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab (2014) 0.85
Reduced elastogenesis: a clue to the arteriosclerosis and emphysematous changes in Schimke immuno-osseous dysplasia? Orphanet J Rare Dis (2012) 0.84
Tacrolimus and ciclosporin microemulsion in renal transplantation. Lancet (2002) 0.84
Identification and characterization of an activating F229V substitution in the V2 vasopressin receptor in an infant with NSIAD. J Am Soc Nephrol (2012) 0.83
Having one kidney does not accelerate the rate of development of diabetic nephropathy lesions in type 1 diabetic patients. Diabetes (2008) 0.83
Estimating mean glomerular volume using two arbitrary parallel sections. J Am Soc Nephrol (2002) 0.83
Normoalbuminuric diabetic kidney disease in the U.S. population. J Diabetes Complications (2012) 0.83
Independent clinical research in Europe. Lancet (2004) 0.83
Temporal profile of diabetic nephropathy pathologic changes. Curr Diab Rep (2013) 0.83
Reversal of diabetic nephropathy: lessons from pancreas transplantation. J Nephrol (2012) 0.81